| Field | Specification |
|---|---|
| Target | |
| Alternative names | Glutamate [NMDA] receptor subunit epsilon-1/2; GRIN2A; NMDAR2A; Glutamate [NMDA; receptor subunit epsilon-1; N-methyl D-aspartate receptor subtype 2A; NMDAR2A; NR2A; hNR2A; GRIN2B; NMDAR2B; Glutamate [NMDA; receptor subunit epsilon-2; N-methyl D-aspartate receptor subtype 2B; NMDAR2B; N |
| Gene ID | |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human NMDAR2A/B around the phosphorylation site of Tyr1246/1252. AA range:1216-1265 |
| Conjugate | |
| Purification | |
| Concentration | |
| Formulation | |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This gene encodes a member of the glutamate-gated ion channel protein family. The encoded protein is an N-methyl-D-aspartate (NMDA) receptor subunit. NMDA receptors are both ligand-gated and voltage-dependent, and are involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. These receptors are permeable to calcium ions, and activation results in a calcium influx into post-synaptic cells, which results in the activation of several signaling cascades. Disruption of this gene is associated with focal epilepsy and speech disorder with or without mental retardation. Alternative splicing results in multiple transcript variants.
Product Overview
This polyclonal antibody, raised in Rabbit, recognizes GRIN2A. It is validated for Western Blot, Immunohistochemistry, Immunofluorescence, ELISA.
Validated Applications
| Applications | Western Blot, Immunohistochemistry, Immunofluorescence, ELISA |
|---|
Optimal dilutions should be determined by the end user for each application and sample type.
Immunogen
The antiserum was produced against synthesized peptide derived from human NMDAR2A/B around the phosphorylation site of Tyr1246/1252. AA range:1216-1265
Specifications
| Host | Rabbit |
|---|---|
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse, Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human NMDAR2A/B around the phosphorylation site of Tyr1246/1252. AA range:1216-1265 |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration | 1 mg/ml |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Target MW | 165283;166367 Da |
| UniProt Accession | Human: Q12879/Q13224; Rat: Q00959/Q00960 |
| Gene ID | Human: 2903/2904; Mouse: 14811/14812; Rat: 24409/24410 |
| Storage | -20°C for 1 year |
| Lead Time | Within one week |
Reactivity Notes
Validated reactivity: Human, Mouse, Rat. For other species, epitope conservation may allow cross-reactivity; confirm with appropriate controls.
Safety & Handling
This product is for research use only (RUO) and is not intended for diagnostic or therapeutic use. The formulation contains sodium azide; handle with standard laboratory precautions.
Related Products
Explore related antibodies and reagents for GRIN2A research from Bioassay Technology Laboratory, or contact us for alternative formats.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
